| Bioactivity | Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors. | ||||||||||||
| Invitro | Ropidoxuridine is an orally bioavailable pro-drug of IUdR (5-iodo-2'-deoxyuridine). Ropidoxuridine demonstrates strong synergy effects with Alisertib at clinically relevant concentrations[1]. | ||||||||||||
| In Vivo | In an orthotopic tumor model, Ropidoxuridine (750 mg/kg/day) and Alisertib (30 mg/kg/day) demonstrate strong synergy effects[1]. | ||||||||||||
| Name | Ropidoxuridine | ||||||||||||
| CAS | 93265-81-7 | ||||||||||||
| Formula | C9H11IN2O4 | ||||||||||||
| Molar Mass | 338.10 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Rampurwala MM, et al. Ropidoxuridine (IPdR) potentiates alisertib (MLN8237) activity in triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-16. |
Ropidoxuridine
CAS: 93265-81-7 F: C9H11IN2O4 W: 338.10
Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for u
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.